Cited by 832Immune Response and InflammationAdvanced Glycation End Products researchInflammation biomarkers and pathways

HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2

Yu, Man, Wang, Haichao, Ding, Aihao, Golenbock, Douglas T., Latz, Eicke, Czura, Christopher J., Fenton, Matthew J., Tracey, Kevin J. +1 more·2006·Shock

Abstract

In response to bacterial endotoxin (e.g., LPS) or endogenous proinflammatory cytokines (e.g., TNF and IL-1beta), innate immune cells release HMGB1, a late cytokine mediator of lethal endotoxemia and sepsis. The delayed kinetics of HMGB1 release makes it an attractive therapeutic target with a wider window of opportunity for the treatment of lethal systemic inflammation. However, the receptor(s) responsible for HMGB1-mediated production of proinflammatory cytokines has not been well characterized. Here we demonstrate that in human whole blood, neutralizing antibodies against Toll-like receptor 4 (TLR4, but not TLR2 or receptor for advanced glycation end product) dose-dependently attenuate HMGB1-induced IL-8 release. Similarly, in primary human macrophages, HMGB1-induced TNF release is dose-dependently inhibited by anti-TLR4 antibodies. In primary macrophages from knockout mice, HMGB1 activates significantly less TNF release in cells obtained from MyD88 and TLR4 knockout mice as compared with cells from TLR2 knockout and wild-type controls. However, in human embryonic kidney 293 cells transfected with TLR2 or TLR4, HMGB1 effectively induces IL-8 release only from TLR2 overexpressing cells. Consistently, anti-TLR2 antibodies dose-dependently attenuate HMGB1-induced IL-8 release in human embryonic kidney/TLR2-expressing cells and markedly reduce HMGB1 cell surface binding on murine macrophage-like RAW 264.7 cells. Taken together, our data suggest that there is a differential usage of TLR2 and TLR4 in HMGB1 signaling in primary cells and in established cell lines, adding complexity to studies of HMGB1 signaling which was not previously expected.

Integrity signals

Registry

Crossref · 10.1097/01.shk.0000225404.51320.82

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several purified endogenous molecules, including HSPs, HMGB1 and uric acid, can induce the production of pro-inflammatory cytokines through TLR2 and/or TLR4 in vitro.

    “Although several of the purified endogenous molecules, including HSPs, HMGb1 and uric acid, can induce the production of pro-inflammatory cytokines through TLR2 and/or TLR4 in vitro25–27, the relevance of these observations has previously been questioned because of the possibility of microbial contamination: several of these proteins, including HSPs and HMGb1, bind lipopolysaccharide (LPS), making”

    From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [26]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., & Yang, H.
Affiliations
  • Feinstein Institute for Medical Research (US)
  • Cornell University (US)
  • University of Massachusetts Chan Medical School (US)
  • University of Maryland, Baltimore (US)
Corresponding author
  • Yu, Man
  • Wang, Haichao
  • Czura, Christopher J.
  • Tracey, Kevin J.
  • Yang, Huan
Venue
Shock
Published
2006-08
Volume
26
Issue
2
Pages
174-179
ISSN
1073-2322 (ISSN-L)
OpenAlex
W2021736304
Cited by
832
References
32
Citations by year
2026: 20 · 2025: 20 · 2024: 26 · 2023: 35 · 2022: 35 · 2021: 40 · 2020: 40 · 2019: 28 · 2018: 42 · 2017: 48 · 2016: 55 · 2015: 53 · 2014: 59 · 2013: 48 · 2012: 62
FWCI
16.82
Type
journal article
Language
en
Open access
closed
Locations
  • Shock (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of General Medical Sciences (R01GM062508)
  • National Center for Research Resources (M01RR018535)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
HMGB1, TLR4, TLR2, HMGB1 signaling, IL-8 release, TNF release, macrophages, MyD88, sepsis, endotoxemia, systemic inflammation, receptor for advanced glycation end products
MeSH terms
Receptor for Advanced Glycation End Products, Animals, Antibodies, Monoclonal, Blood Cells, Cell Line, Cricetulus, Dose-Response Relationship, Drug, Dose-Response Relationship, Immunologic, Cricetinae, Humans, Receptors, Immunologic, Tumor Necrosis Factor-alpha, Signal Transduction, Interleukin-8, CHO Cells, Glycation End Products, Advanced, Mice, Knockout, HMGB1 Protein, Toll-Like Receptor 2, Toll-Like Receptor 4, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review